Breaking News

Cellectis to Build Mfg. Facility in North Carolina

With help from CMO partners, advances further towards commercialization of UCART portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellectis, a biopharma company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), has entered into a lease agreement to build an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, NC, for clinical and commercial production of Cellectis’ leading allogeneic UCART products. In addition, Cellectis started building a 14,000 square foot manufacturing facility in P...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters